Search
Opicapone
go.drugbank.com/drugs/DB11632ApprovedInvestigationalOpicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020.[L13772] It is marketed under the brand name Ongentys as once-daily oral capsules. … Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily [L2336] and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase
Histrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawn[L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. … As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700]
Categories: Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor AgonistsVelmanase alfa
go.drugbank.com/drugs/DB12374ApprovedInvestigationalVelmanase alfa has an amino acid sequence of the monomeric protein identical to the naturally occurring human alpha-mannosidase. … The resulting accumulation of sugars in the body leads to an array of clinical manifestations leading to progressive neuromuscular and skeletal deterioration, such as skeletal abnormalities, motor function
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type … [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically
Categories: VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsProducts: ABXEDA EPolycarbophil
go.drugbank.com/drugs/DB09311ApprovedWithdrawnPolycarbophil calcium is a stool stabilizer used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. … The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability,
Acetylcarnitine
go.drugbank.com/drugs/DB08842ApprovedInvestigationalThe main role of acetylcarnitine is to help transport fatty acids into the mitochondrial matrix where fatty acid metabolism occurs. … In human plasma and tissues, acetylcarnitine is the most predominant acylated ester of carnitine, which is an amino acid derivative that is made in the kidney, liver, and brain from lysine and methionine
Gefapixant
go.drugbank.com/drugs/DB15097Approved[L48596] Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough. … [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601]
Amifampridine
go.drugbank.com/drugs/DB11640ApprovedThis leads to the reduction of the compound muscle action potential (CMAP) [A33863]. … Reduced acetylcholine release at the neuromuscular junction leads to decreased frequency of miniature endplate potentials of normal amplitude, and insufficient acetylcholine levels for the activation of
Nisoldipine
go.drugbank.com/drugs/DB00401ApprovedNisoldipine may be used in alone or in combination with other agents in the management of hypertension. … By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction.
International brands: Ji Ni Le ErLusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). … Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta.
Categories: Thrombopoietin Receptor Agonist